SCHEMBL280167

SCHEMBL280167

CCOC(=O)c1c(C)oc(-c2ccccc2)c1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
MAPT P10636 4/20 0.56
LMNA P02545 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
APAF1 O14727 1/20 0.56
MITF O75030 1/20 0.56
GAA P10253 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
HPGD P15428 6/20 0.53
NPSR1 Q6W5P4 3/20 0.53
GRM6 O15303 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
KDM4E B2RXH2 7/20 0.52
RAB9A P51151 2/20 0.52
TP53 P04637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NPC1 O15118 1/20 0.51
PTGS2 P35354 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12755569 0.80 MAPT (0.50) ALDH1A1MAPTLMNASMN1; SMN2APAF1
SCHEMBL3907147 0.76 ALDH1A1 (0.51) ALDH1A1MAPTLMNASMN1; SMN2APAF1
SCHEMBL25194957 0.76 CA12 (0.56) ALDH1A1MAPTLMNASMN1; SMN2APAF1
SCHEMBL8872491 0.75 MEN1 (0.74) ALDH1A1MAPTSMN1; SMN2GAAMEN1
SCHEMBL1753377 0.74 CYP1A2 (0.51) ALDH1A1MAPTLMNASMN1; SMN2GAA
SCHEMBL4031918 0.73 ALDH1A1 (0.65) ALDH1A1MAPTLMNASMN1; SMN2GAA
SCHEMBL10462774 0.73 MEN1 (0.57) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL27569291 0.73 ALDH1A1 (0.57) ALDH1A1MAPTLMNASMN1; SMN2APAF1
SCHEMBL31526266 0.72 PTGS1 (0.72) ALDH1A1MAPTLMNASMN1; SMN2GAA
SCHEMBL11337306 0.72 GRM6 (0.58) ALDH1A1MAPTLMNAGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8552031-B2 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-08 US disclosed
US-8318796-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-11-27 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2011-03-31 US disclosed
US-20090281317-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2009-11-12 US disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
EP-1253146-B1 Process for the synthesis of substituted furancarboxylates DSM FINE CHEM AUSTRIA GMBH (AT) 2003-09-10 EP disclosed
EP-1253146-A1 Process for the synthesis of substituted furancarboxylates DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) 2002-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 ALDH1A1 3234/4885MAPT 3117/4885LMNA 4688/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 ALDH1A1 3206/4885MAPT 2880/4885LMNA 4674/4885
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL ALDH1A1 2047/4885MAPT 311/4885LMNA 1745/4885
US-20090281317-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS MPL, TEK, THPO ALDH1A1 1864/4885MAPT 746/4885LMNA 1814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.